

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer

Justin F. Gainor¹, Anna M. Varghese³, Sai-Hong Ignatius Ou⁵, Sheheryar Kabraji¹, Mark M. Awad¹, Ryohei Katayama¹, Amanda Pawlak², Mari Mino-Kenudson², Beow Y. Yeap¹, Gregory J. Riely³, A. John Iafrate², Maria E. Arcila⁴, Marc Ladanyi⁴, Jeffrey A. Engelman¹, Dora Dias-Santagata², and Alice T. Shaw¹

Abstract

Purpose: Anaplastic lymphoma kinase (*ALK*) gene rearrangements define a distinct molecular subset of non-small cell lung cancer (NSCLC). Recently, several case reports and small series have reported that *ALK* rearrangements can overlap with other oncogenic drivers in NSCLC in crizotinib-naïve and crizotinib-resistant cancers.

Experimental Design: We reviewed clinical genotyping data from 1,683 patients with NSCLC and investigated the prevalence of concomitant *EGFR* or *KRAS* mutations among patients with *ALK*-positive NSCLC. We also examined biopsy specimens from 34 patients with *ALK*-positive NSCLC after the development of resistance to crizotinib.

Results: Screening identified 301 (17.8%) *EGFR* mutations, 465 (27.6%) *KRAS* mutations, and 75 (4.4%) *ALK* rearrangements. *EGFR* mutations and *ALK* rearrangements were mutually exclusive. Four patients with *KRAS* mutations were found to have abnormal *ALK* FISH patterns, most commonly involving isolated 5' green probes. Sufficient tissue was available for confirmatory *ALK* immunohistochemistry in 3 cases, all of which were negative for *ALK* expression. Among patients with *ALK*-positive NSCLC who acquired resistance to crizotinib, repeat biopsy specimens were *ALK* FISH positive in 29 of 29 (100%) cases. Secondary mutations in the *ALK* kinase domain and *ALK* gene amplification were observed in 7 of 34 (20.6%) and 3 of 29 (10.3%) cases, respectively. No *EGFR* or *KRAS* mutations were identified among any of the 25 crizotinib-resistant, *ALK*-positive patients with sufficient tissue for testing.

Conclusions: Functional *ALK* rearrangements were mutually exclusive with *EGFR* and *KRAS* mutations in a large Western patient population. This lack of overlap was also observed in *ALK*-positive cancers with acquired resistance to crizotinib. *Clin Cancer Res*; 19(15); 4273–81. ©2013 AACR.

Introduction

Treatment paradigms for non-small cell lung cancer (NSCLC) have recently shifted away from stratification of patients based upon histology alone and toward molecular classifications based on genetic alterations within "driver" oncogenes. NSCLCs harboring such alterations are often dependent on a single oncogenic pathway for cell survival, a concept known as oncogene addiction (1). In recent geno-

typing efforts, approximately 50% of pulmonary adenocarcinomas were identified as having at least one genetic alteration in an oncogenic driver, with higher rates observed among never-smokers (2–4). Notably, mutations within driver oncogenes are largely mutually exclusive with one another, overlapping in only 3% to 5% of cases (2, 3).

Identified in NSCLC in 2007, chromosomal rearrangements involving the anaplastic lymphoma kinase (*ALK*) gene define a new molecular subset of lung cancer (5). With an estimated frequency of 3% to 5% of NSCLC, *ALK* rearrangements are associated with unique clinical and pathologic features, including younger age, never or light smoking history, and adenocarcinoma histology (6–9). *ALK* rearrangements are also regarded as essentially mutually exclusive with mutations in other driver oncogenes (7, 10). However, several recent reports suggest an unexpectedly high degree of overlap between *ALK* rearrangements and mutations in *KRAS* or *EGFR* (3, 11–19). For example, in a recent analysis of 95 *EGFR*-mutant patients who participated in the phase III EURTAC trial, 15.8% were

Authors' Affiliations: Departments of ¹Medicine and ²Pathology, Massachusetts General Hospital, Boston, Massachusetts; Departments of ³Medicine and ⁴Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York; and ⁵Department of Medicine, University of California, Irvine, Orange, California

Corresponding Author: Alice T. Shaw, Department of Medicine, Massachusetts General Hospital Cancer Center, 32 Fruit Street, Boston, MA 02114. Phone: 617-724-4000; Fax: 617-726-0453; E-mail: ashaw1@partners.org

doi: 10.1158/1078-0432.CCR-13-0318

©2013 American Association for Cancer Research.

Translational Relevance

Lung cancers harboring chromosomal rearrangements involving the anaplastic lymphoma kinase (*ALK*) gene are associated with unique clinicopathologic features, including sensitivity to the tyrosine kinase inhibitor (TKI) crizotinib. Recently, several studies have suggested that *ALK* rearrangements co-occur with mutations in *EGFR* or *KRAS* at clinically relevant frequencies. If confirmed, this would have important consequences for therapeutic decision-making and may alter clinical laboratory workflow, as many centers reserve *ALK* testing for tumor specimens that are negative for mutations in *EGFR* and *KRAS*. Here, we present clinical genotyping data from 1,683 patients with NSCLC, focusing on the prevalence of *EGFR* and *KRAS* mutations in *ALK*-positive patients. We also report molecular studies on a cohort of 34 *ALK*-positive patients who underwent biopsies after the development of resistance to crizotinib to determine the prevalence of acquired *EGFR* and *KRAS* mutations in this population.

reported to have concomitant *ALK* rearrangements (20). Additional studies have identified the coexistence of *EGFR* mutations in up to 6% of *ALK*-positive patients within Western populations and in up to 11.8% among *ALK*-positive Asian populations (16, 18).

Recognition of *ALK*-positive patients is clinically important as *ALK* rearrangements are associated with marked sensitivity to the tyrosine kinase inhibitor (TKI) crizotinib. In early clinical studies of crizotinib in *ALK*-positive NSCLC, the objective response rate was 60% with median progression-free survival of 8 to 10 months (21–23). Despite the initial sensitivity of *ALK*-positive lung cancer to crizotinib, patients eventually develop resistance to therapy. Mechanisms of acquired crizotinib resistance have been identified *in vitro* and through molecular analysis of repeat biopsy specimens taken at the time of disease progression (16, 24–28). These include secondary mutations in the *ALK* tyrosine kinase (TK) domain, *ALK* fusion gene amplification, and upregulation of bypass signaling tracts, such as c-KIT and *EGFR* (16, 24, 26–28). In addition, one study reported loss of the *ALK* fusion gene and emergence of *EGFR* and *KRAS* mutations in crizotinib-resistant cancers (27).

The possibility of coexistence of *ALK* fusions and either *EGFR* or *KRAS* mutations would have profound effects on therapeutic choices and would also impact clinical laboratory workflow and resource allocation as many centers now reserve *ALK* FISH testing, a relatively labor-intensive assay, for cases that test negative for *EGFR* and *KRAS* mutations. In this multi-institutional study, we identified patients who underwent clinical genotyping for alterations in *EGFR*, *KRAS*, and *ALK*, examining the prevalence of coexisting *EGFR* or *KRAS* mutations among *ALK*-positive patients. We also present an updated analysis of a series of repeat biopsies from crizotinib-resistant, *ALK*-positive patients (26) to

determine the frequency of *EGFR* and *KRAS* mutations in TKI-resistant disease.

Materials and Methods

Study populations

Patients ($n = 1,683$) with NSCLC who underwent non-sequential testing for mutations in *EGFR*, *KRAS*, and *ALK* between March 2009 and June 2012 were identified. Patients were seen at Massachusetts General Hospital (MGH; $n = 1,619$), Memorial Sloan-Kettering Cancer Center ($n = 33$), and the University of California at Irvine ($n = 31$). All patients had biopsy-proven NSCLC. Medical records were reviewed to extract data on clinical and pathologic features. This study was approved by the Institutional Review Board at each of the participating institutions.

Patients with *ALK*-positive NSCLC ($n = 34$) with acquired resistance to crizotinib underwent biopsies of their resistant tumors at one institution (MGH) between January, 2009 and October, 2012. Specimens were reviewed for histologic confirmation of malignancy. Total nucleic acid was extracted in all specimens for *ALK* TK domain sequencing as outlined below. Repeat *ALK* FISH and the multiplexed SNaPshot assay were conducted in all specimens with sufficient tissue for analysis.

Tumor pathology and mutation analysis

Tumor histology was classified according to World Health Organization criteria. *EGFR* and *KRAS* testing were conducted using SNaPshot (29). In cases where SNaPshot was unavailable, mutation analysis was conducted by a combination of a multiplexed PCR-based sizing assay, allele-specific PCR, direct sequencing and mass spectrometry genotyping.

ALK molecular analysis

ALK FISH was conducted on formalin-fixed and paraffin-embedded (FFPE) tissue using a dual-color break-apart probe specific to the *ALK* locus (Vysis LSI *ALK* Dual Color, Break Apart Rearrangement Probe; Abbott Molecular). Samples were considered positive if more than 15% of cells showed split *ALK* 5' and 3' probe signals or isolated 3' signals (7).

In *ALK*-positive, crizotinib-resistant biopsy specimens, total nucleic acid was extracted and the *ALK* TK domain (exons 20–28) was sequenced as previously described (26).

Immunohistochemistry

Immunohistochemical staining was conducted on representative tissue sections from FFPE tissue blocks. Immunohistochemistry (IHC) was conducted with an anti-*ALK* monoclonal antibody (clone 5A4, Novacastra) at 1:50 dilution (30).

Statistical analysis

Fisher exact test and Wilcoxon rank-sum test were used to assess the association of genotype status with clinicopathologic features. An exact calculation of the binomial distribution is used to obtain the upper bound of a one-sided

Table 1. Clinicopathologic features of *EGFR*, *KRAS*, and *ALK*-positive patients

Clinical characteristic	<i>EGFR</i> (n = 301)	<i>KRAS</i> (n = 465)	<i>ALK</i> (n = 75)	P-value for <i>ALK</i> vs. <i>EGFR</i>	P-value for <i>ALK</i> vs. <i>KRAS</i>
Age at diagnosis				<0.001	<0.001
Median	64	66	56		
Range	26–92	26–92	29–87		
Sex				<0.001	0.022
Male	86 (29%)	170 (37%)	38 (51%)		
Female	215 (71%)	295 (63%)	37 (49%)		
Ethnicity ^a				0.192	<0.001
Caucasian	227 (76%)	436 (96%)	64 (85%)		
Asian	47 (16%)	8 (2%)	9 (12%)		
Other	23 (8%)	11 (2%)	2 (3%)		
Smoking History ^b				0.239	<0.001
Never	173 (57%)	18 (4%)	49 (65%)		
Smoker	128 (43%)	445 (96%)	26 (35%)		
Pathology				0.104	0.072
Adenocarcinoma	287 (95%)	432 (93%)	71 (95%)		
Adenosquamous	6 (2%)	9 (2%)	0 (0%)		
Squamous	2 (1%)	4 (1%)	3 (4%)		
Other NSCLC	6 (2%)	20 (4%)	1 (1%)		
Stage ^c				<0.001	<0.001
Stage I	78 (26%)	175 (38%)	4 (5%)		
Stage II	16 (5%)	55 (12%)	8 (11%)		
Stage III	43 (14%)	69 (15%)	18 (24%)		
Stage IV	163 (55%)	165 (35%)	45 (60%)		
Stage at Testing ^d				0.002	<0.001
Stage I	68 (23%)	158 (34%)	4 (5%)		
Stage II	14 (5%)	47 (10%)	4 (5%)		
Stage III	33 (11%)	56 (12%)	12 (16%)		
Stage IV	185 (62%)	204 (44%)	55 (74%)		

^aOther includes "Hispanic," "African-American," and "Native American" ethnicities. Ethnicity was unavailable in 14 patients.

^bNever smokers have smoked less than 100 cigarettes per lifetime. Smokers have smoked more than 100 cigarettes (current or former). Smoking status was unavailable in 2 patients.

^cClinical stage represents stage at initial diagnosis. Stage was determined according to current American Joint Commission on Cancer Guidelines. Stage was not available for 2 patients.

^dRepresents stage at time of molecular testing. Stage was not available for 1 patient.

95% CI for the frequency of *ALK*-positive cases with a second driver mutation. Data analysis was computed by SAS 9.2 (SAS Institute), and all *P* values were two-sided.

Results

Screening patient characteristics

We identified 1,687 NSCLC specimens that had undergone clinical genotyping for abnormalities in *EGFR*, *KRAS*, and *ALK*. Testing for each genetic alteration was conducted in 100% of specimens. A total of 1,683 patients were included, with 4 patients having 2 separate primary NSCLCs analyzed. Genotyping for *EGFR* and *KRAS* mutations was conducted using the SNaPshot assay in 1,603 (95.1%) cases. Mutations in *EGFR* and *KRAS* were identified in 301 (17.8%) and 465 (27.6%) specimens, respectively. *ALK* FISH was conducted on all samples. *ALK* rearrangements

were found in 75 (4.4%) cases. The clinical and pathologic features of these patients are summarized in Table 1.

Lack of overlapping mutations in driver oncogenes

The overall frequency of coalterations among any of the 3 tested oncogenes was 0.06% (1/1,687). Only 1 case of overlap, involving concomitant mutations in *EGFR* and *KRAS*, was observed by allele-specific PCR. Insufficient tumor tissue was available for confirmatory SNaPshot testing of this specimen. Among 376 patients found to have *EGFR* mutations (*n* = 301) or *ALK* rearrangements (*n* = 75), there were no cases of coexisting *EGFR* and *ALK* alterations identified.

Four patients with *KRAS* mutations were noted to have abnormal *ALK* FISH patterns that did not meet criteria for the presence of an *ALK* rearrangement (Table 2). Such

Downloaded from http://aacrjournals.org/clinoncres/article-pdf/19/15/4273/2013683/4273.pdf by guest on 21 July 2024

Table 2. Molecular analysis of patients with *KRAS* mutations and abnormal ALK FISH

Patient no.	<i>EGFR</i> mutation	<i>KRAS</i> mutation	ALK FISH pattern	ALK IHC
1	WT	Gly12Cys	Isolated green 5' probe	Negative
2	WT	Gly12Ser	Isolated green 5' probe	Negative
3	WT	Gly13Cys	Isolated green 5' probe	N/A
4	WT	Gly12Val	Isolated red 3' probe ^a	Negative

^aALK FISH—isolated red 3' probe considered "unusually small."

abnormal ALK FISH patterns involved single isolated green 5' probes in 3 (75%) cases. The last case involved an ALK FISH pattern with a single isolated red 3' probe that was considered unusually small. To determine whether these cases harbored functional *ALK* rearrangements leading to expression of an ALK fusion protein, ALK immunohistochemistry (clone 5A4) was conducted. Previous immunohistochemical studies using the ALK 5A4 antibody have shown a sensitivity and specificity of 100% among 29 ALK FISH-positive adenocarcinoma specimens and 110 ALK FISH-negative samples (30). Sufficient tissue was available for ALK immunohistochemical testing in 3 of the *KRAS*-positive, abnormal ALK FISH cases. Immunohistochemistry was negative for ALK expression in 3/3 (100%) specimens, including the case with an isolated, unusually small red 3' probe on ALK FISH (Fig. 1). Thus, these abnormal ALK FISH patterns were not consistent with functional *ALK* gene rearrangements. Therefore, altogether 0 of 75 (0%; upper 95% CI: 4%) patients with *ALK* rearrangements were found to have concomitant mutations in *EGFR* or *KRAS* (Table 3).

Repeat biopsies in ALK-positive, crizotinib-refractory NSCLC

We previously reported an analysis of crizotinib resistance in 18 ALK-positive patients who underwent repeat biopsies at the time of progression (26). Here, we present an

updated and expanded analysis of 34 repeat biopsy specimens from ALK-positive, crizotinib-refractory patients. Specimens were examined for mechanisms of acquired resistance. In all cases, patients had initially responded to crizotinib but subsequently developed progressive disease after a median of 9 months (range 3–34 months). A majority of repeat biopsies were obtained before or within 1 month of crizotinib discontinuation (Table 4). If sufficient tissue was available, specimens underwent repeat ALK FISH, direct sequencing of the *ALK* TK domain, and SNaPshot testing.

Persistence of the ALK fusion gene at the time of acquired crizotinib resistance

Our earlier report of acquired resistance to crizotinib in patients with *ALK* rearrangements showed the continued presence of the *ALK* fusion transcript upon rebiopsy (26). However, it has recently been reported that patients may lose the *ALK* gene rearrangement upon treatment with crizotinib (27). We therefore conducted repeat ALK FISH testing on the additional crizotinib-resistant specimens. Among 34 specimens, a total of 29 were evaluable. Tumor material in the remaining 5 samples was exhausted due to sequencing efforts. Notably, in 29 of 29 (100%) cases, repeat ALK FISH confirmed the continued presence of an *ALK* fusion gene despite acquired resistance to crizotinib (Tables 4 and 5).




Figure 1. Immunohistochemical staining for ALK. Specimens (A–C) show negative ALK immunohistochemical staining for 3 patients with *KRAS* mutations and abnormal ALK FISH. Specimens (D–F) depict positive ALK immunohistochemical staining from 3 representative patients with positive ALK FISH.

Table 3. Summary of overlapping mutations in *EGFR*, *KRAS*, and *ALK*

# Single mutations	<i>EGFR</i>	<i>KRAS</i>	<i>ALK</i>
<i>EGFR</i> (n = 301)	–	1	0
<i>KRAS</i> (n = 465)	1	–	0
<i>ALK</i> (n = 75)	0	0	–

Gene amplification has been reported to mediate resistance in a number of oncogene-driven malignancies (31, 32), including *ALK*-rearranged NSCLC (26–28). In our crizotinib-resistant cohort, repeat *ALK* FISH also permitted detection of gene amplification. In 2 patients (MGH029 and MGH034), *ALK* FISH was notable for high-level amplification, and a third specimen (MGH044) showed low-level gene amplification. In total, 3 of 29 (10.3%) patients exhibited amplification of the *ALK* gene at the time of crizotinib resistance.

Secondary mutations in *ALK* TK domain as mediators of crizotinib resistance

We next evaluated crizotinib-resistant specimens for secondary mutations in the *ALK* TK domain. Total nucleic acid was extracted and direct sequencing of the *ALK* TK domain was carried out as described previously (26). Among 34 tested specimens, a total of 8 secondary mutations were identified among 7 (20.6%) patients (Tables 4 and 5). The resistant specimen from MGH021 contained 2 separate secondary mutations: an amino acid substitution (G1269A) and an insertion mutation (1151Tins). A majority of secondary mutations involved missense mutations (S1206Y, G1202R, L1196M, and G1269A), all of which have been previously reported as mediators of crizotinib resistance (24, 26, 27). The most frequently identified secondary mutation was the gatekeeper L1196M mutation. However, this substitution was present in only 3 (9.3%) specimens, underscoring that the *ALK* gatekeeper mutation is not the dominant mechanism of crizotinib resistance.

Absence of *EGFR* and *KRAS* mutations in crizotinib-resistant cancers

Aberrant coactivation of *EGFR* signaling, in the absence of *EGFR* mutations, has been observed as a mechanism of crizotinib resistance *in vitro* and within patient-derived specimens (16, 26). One recent report also identified the emergence of *EGFR* and *KRAS* mutations among 11 *ALK*-positive patients following development of resistance to crizotinib (27). In a separate study of 7 *ALK*-positive patients with acquired crizotinib resistance, 1 patient was found to have *ALK* gene amplification as well as *EGFR* high polysomy and an acquired *EGFR* L858R mutation (28). We therefore tested repeat biopsy specimens from crizotinib-resistant, *ALK*-positive patients for mutations in *EGFR* and *KRAS* using the SNaPshot assay (Table 4). In 25 patients with available tissue, *EGFR* mutations were identified in 0 of 25 (0%; upper 95% CI: 11%) cases. Similarly, *KRAS* muta-

tions were found in 0 of 25 (0%; upper 95% CI: 11%) specimens.

Discussion

In NSCLC, genetic alterations in *EGFR*, *KRAS*, and *ALK* are considered to be largely mutually exclusive (7, 10, 33). However, recent series have suggested that *EGFR* mutations and *ALK* rearrangements coexist within patients at clinically meaningful frequencies (3, 15–19). The question of whether overlap exists between these driver oncogenes is clinically relevant and would impact therapeutic choices. *In vitro* studies suggest that concomitant alterations in *EGFR* and *ALK* lead to mutual resistance to *EGFR* or *ALK* TKI monotherapy (16). In limited clinical series of patients reported to have both alterations, isolated responses to erlotinib, gefitinib, and crizotinib have been described (11, 12, 16, 18, 19). However, to the best of our knowledge, there have been no reports in which individual patients with co-existing *EGFR* mutations and *ALK* rearrangements responded to both *EGFR* and *ALK* TKIs.

In this study, we examined a large Western population of patients with NSCLC who underwent clinical genotyping. In contrast to the reports mentioned above, we found no cases of coexisting *EGFR* mutations and *ALK* rearrangements across 1,687 screened specimens, supporting the mutual exclusivity of these 2 genetic alterations. We did identify a few cases of concomitant *KRAS* mutations and abnormal *ALK* FISH. While abnormal, however, these FISH patterns did not meet criteria for an *ALK* rearrangement. Specifically, most cases (3/4) involved single isolated green 5' probes, rather than the typical split probe or isolated 3' probe pattern. To confirm the absence of a functional *ALK* rearrangement in these specimens, *ALK* immunohistochemistry was conducted and found to be negative in 3 of 3 cases tested. In a prior series using this antibody, *ALK* immunohistochemistry had a negative predictive value of 100% (30). Thus, these findings are unlikely to be due to false-negative staining, as the probability of obtaining 3 false-negative immunohistochemical results among these cases would be less than 0.00001. We therefore conclude that these abnormal *ALK* FISH patterns are unlikely to represent functional *ALK* gene rearrangements. Altogether, these findings support the lack of overlap between *ALK* rearrangements and either *EGFR* or *KRAS* mutations.

We recognize that these findings are in contrast to some recent reports (14–19). One explanation for such discordant findings may involve ethnic differences between screening populations. Specifically, the higher prevalence of *EGFR* mutations within Asian NSCLC populations may increase the chance of detecting dual *EGFR* and *ALK* alterations (34). Indeed, the highest frequencies of concomitant *EGFR* mutations and *ALK* rearrangements have been reported in Asian populations (17–19). For instance, in one study describing concomitant *EGFR* mutations in 11.8% of patients with *ALK* rearrangements, the overall prevalence of *EGFR* mutations in the study population (n = 444) was 51.4% (18).

Table 4. ALK-positive patients with acquired crizotinib resistance

Patient	Timing (months) ^a	Duration (months) ^b	ALK fusion	ALK amplification	ALK secondary mutation	EGFR mutation	KRAS mutation
MGH0NZ	0	20	Positive	No	No	WT	WT
MGH001	4.5	4	Positive	No	No	WT	WT
MGH010	0	8	Positive	No	No	WT	WT
MGH011	0	34	Positive	No	S1206Y	WT	WT
MGH013	0	9	Positive	No	No	WT	WT
MGH016	6	6	Positive	No	No	WT	WT
MGH017	0	23+	Positive	No	No	WT	WT
MGH018	0.5	10	Positive	No	G1202R	N/A	N/A
MGH019	<0.5	8	Positive	No	No	WT	WT
MGH020	0	13	N/A	N/A	L1196M	N/A	N/A
MGH021	3	12	Positive	No	1151Tins, G1269A	WT	WT
MGH022	0	6	Positive	No	No	WT	WT
MGH023	0	12	Positive	No	No	WT	WT
MGH024	0	15	Positive	No	No	N/A	N/A
MGH025	0	11	N/A	N/A	No	WT	WT
MGH027	1	4	N/A	N/A	No	N/A	N/A
MGH028	1	14	N/A	N/A	No	N/A	N/A
MGH029	0	8	Positive	Yes	No	N/A	N/A
MGH030	0	9	Positive	No	No	WT	WT
MGH031	N/A	N/A	Positive	No	No	WT	WT
MGH032	21	9	Positive	No	No	N/A	N/A
MGH033	0	3	Positive	No	No	WT	WT
MGH034	0	8	Positive	Yes	No	WT	WT
MGH035	N/A	14	Positive	No	No	WT	WT
MGH036	0.5	13	Positive	No	No	WT	WT
MGH037	0	11	Positive	No	G1269A	WT	WT
MGH038	0	7	Positive	No	L1196M	WT	WT
MGH040	0	9	Positive	No	No	WT	WT
MGH044	0	5	Positive	Yes ^c	No	WT	WT
MGH045	0	13	Positive	No	L1196M	N/A	N/A
MGH051	<0.5	3	Positive	No	No	WT	WT
MGH054	8.5	3	Positive	No	No	WT	WT
MGH055	0	3	N/A	N/A	No	N/A	N/A
MGH058	0	14	Positive	No	No	WT	WT

^aIndicates the time interval between last crizotinib dose and repeat biopsy. Repeat biopsies conducted while the patient is still receiving crizotinib are depicted with a "0".

^bIndicates the approximate duration the patient was treated with crizotinib.

^cLow level ALK amplification.

In addition to ethnic variations, our findings may differ from other reports due to the stage distribution of our patient population. A significant proportion of patients in this study had early-stage disease at the time of mutation testing. It is therefore possible that we did not capture

additional genetic alterations that may have accumulated later during the disease course. Another potential explanation for reports of dual genetic alterations may be the presence of multiple separate primary tumors in patients, each harboring different driver mutations. When

Table 5. Summary of ALK-positive, crizotinib-refractory cases

Resistant cases	ALK fusion	ALK amplification	ALK secondary mutation	EGFR mutation	KRAS mutation
34	29/29 (100%)	3/29 (10.3%)	7/34 (20.6%)	0/25 (0%)	0/25 (0%)

overlapping genetic alterations in *ALK* and *EGFR* are suspected, *ALK* and *EGFR* mutant-specific immunohistochemistry may help distinguish whether both abnormalities are colocalized in the same cells. Our findings may also differ from those of prior studies due to possible reporting bias and choice of screening techniques. *ALK* testing can be conducted using *ALK* immunohistochemistry, reverse transcription PCR (RT-PCR), and *ALK* FISH. While *ALK* FISH is the only clinically validated assay and current gold standard, this technique is technically challenging (35). In prior reports of coexisting *EGFR* mutations and *ALK* rearrangements, various methods of *ALK* testing were used, including *ALK* FISH, *ALK* immunohistochemistry, RT-PCR, and rapid amplification of cDNA ends (RACE)-coupled PCR (11–19). In contrast, all patients in our study were screened using *ALK* FISH. Of note, *ALK* FISH positivity in this study was defined as more than 15% of cells showing positive signals. This is consistent with the definition of *ALK* positivity used in clinical trials of crizotinib, and this threshold is above the technical background noise of the assay (21, 36).

As the molecular profile of malignancies may evolve over the course of treatment, we also examined the molecular characteristics of *ALK*-positive cancers after the development of resistance to crizotinib. Crizotinib-resistant specimens were examined for *ALK* gene amplification, secondary *ALK* TK domain mutations, and emergence of *EGFR* and *KRAS* mutations. Of particular note, we found that the presence of the *ALK* fusion gene as assessed by FISH was preserved across all tested specimens despite the presence of acquired crizotinib resistance. This finding is consistent with the oncogene addiction paradigm as well as results from repeat biopsy series in patients with *EGFR* mutations and acquired resistance to *EGFR* inhibitors (32, 37). Although we and others have previously identified ligand-dependent activation of *EGFR* as a potential resistance mechanism to crizotinib (16, 26, 38), we found no cases of *EGFR* or *KRAS* mutations among 25 examined specimens, including those cases with upregulation of activated *EGFR* by immunohistochemistry. Thus, our findings are different from a previous study reporting that *ALK*-positive patients develop *ALK*-negative tumors harboring new mutations in *EGFR* following treatment with crizotinib (27). It remains possible that the patients identified in the other study had 2 separate primary cancers, an *EGFR*-mutant lung cancer and an *ALK*-positive lung cancer, and the *EGFR*-mutant lung cancer emerged upon treatment with crizotinib. In such cases, more comprehensive genetic analyses may inform whether pretreatment and resistant cancers are derived from a common ancestor clone. Nevertheless, our findings on a larger cohort of patients, suggest that such occurrences will be rare in cancers with acquired crizotinib resistance.

Our study has several implications. In rare cases of suspected overlapping genetic alterations in driver oncogenes, our findings underscore the importance of using confirmatory molecular testing, preferably using different

genotyping techniques. Our findings may also affect clinical laboratory workflow and resource allocation since the lack of concomitant genetic alterations in *EGFR*, *KRAS*, and *ALK* may permit sequential genetic testing in centers where *ALK* FISH is not readily available. However, this must be balanced against the need for timely acquisition of genotyping data to guide rapid initiation of therapy, particularly at the time of diagnosis. For this reason, a simultaneous molecular testing strategy also remains a viable approach. Finally, this study has implications for our understanding of crizotinib resistance. Consistent with prior reports, we observed *ALK* fusion gene amplification and secondary mutations in the *ALK* TK domain in a subset of *ALK*-positive patients with acquired crizotinib resistance. Nonetheless, the number of crizotinib-resistant patients examined in this and other studies have been relatively small, and a significant proportion of these patients still have unknown mechanisms of resistance to date. Resistance is likely to be a molecularly complex process, and studies of repeat biopsies in larger cohorts of crizotinib-resistant patients are needed.

There are several potential limitations to our study. It is possible that we did not detect genetic alterations present at very low allelic frequencies within our study population. To minimize this likelihood, all *ALK* testing was conducted using the current gold-standard assay, *ALK* FISH. Moreover, *EGFR* and *KRAS* mutation testing was conducted using the SNaPshot assay, which has analytic sensitivity to detect mutations present at a frequency of approximately 5% (29). Another consideration is that mutations in *EGFR* or *KRAS* may have been present, but they were outside of the mutation hotspot regions designated in our multiplexed assays. This is less likely as more than 95% of mutations in both *EGFR* and *KRAS* are captured by these assays. One last consideration is the presence of intratumoral heterogeneity. In this study, molecular testing was conducted on a single biopsy or resection specimen and thus, may not be reflective of all sites of disease. This is mainly relevant to treatment resistant specimens, as studies have shown clonality of driver gene alterations in pretreatment samples (39, 40). However, if this were a common occurrence in resistance, one would have expected to observe an *EGFR* or *KRAS* mutation in at least one of the resistant biopsies examined.

Finally, while this manuscript was under review, 2 smaller screening studies were published, confirming similar findings in 208 and 99 patients, respectively (41, 42). Together, our analyses provide support for the mutual exclusivity of alterations in *EGFR*, *KRAS*, and *ALK* within the Western population. By examining a series of biopsy specimens from *ALK*-positive patients after development of resistance to crizotinib, we also show that this lack of overlap persists in the resistant cancers.

Disclosure of Potential Conflicts of Interest

A.J. Iafrate is employed (other than primary affiliation; e.g., consulting) as a consultant in Pfizer and Bioreference Labs. J.A. Engelman has a commercial research grant from Novartis, Sanofi-Aventis, and AstraZeneca; has

ownership interest (including patents) in Gatekeeper; and is a consultant/advisory board member of Novartis, Sanofi-Aventis, Chugai, and AstraZeneca. D. Dias-Santagata is a consultant/advisory board member of BioReference Laboratories, Inc. A.T. Shaw is a consultant/advisory board member of Pfizer, Novartis, Ariad, Chugai, and Daiichi Sankyo. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: J.F. Gainor, A.M. Varghese, G.J. Riely, M.E. Arcila, M. Ladanyi, J.A. Engelman, A.T. Shaw

Development of methodology: J.F. Gainor, R. Katayama, G.J. Riely, M.E. Arcila

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.F. Gainor, A.M. Varghese, S.H. Ignatius Ou, S. Kabraji, M.M. Awad, R. Katayama, M. Mino-Kenudson, G.J. Riely, A.J. Iafrate, M.E. Arcila, D. Dias-Santagata, A.T. Shaw

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.F. Gainor, S.H. Ignatius Ou, M.M. Awad, B.Y. Yeap, A.J. Iafrate, M.E. Arcila, M. Ladanyi, J.A. Engelman, D. Dias-Santagata, A.T. Shaw

Writing, review, and/or revision of the manuscript: J.F. Gainor, S.H. Ignatius Ou, M. Mino-Kenudson, B.Y. Yeap, G.J. Riely, A.J. Iafrate, M.E. Arcila, M. Ladanyi, J.A. Engelman, A.T. Shaw

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.F. Gainor, S. Kabraji, M.M. Awad, A. Pawlak

Study supervision: G.J. Riely, M.E. Arcila, A.T. Shaw

Acknowledgments

The authors thank Emily Howe at Massachusetts General Hospital for help in coordinating clinical testing of crizotinib-resistant specimens. They also thank "Be a Piece of the Solution" and the "Evan Spirito Memorial Foundation" for support of lung cancer research.

Grant Support

This work was supported by grants from the U.S. NIH 5R01CA164273-02 and 5P50CA090578-10, and by a V Foundation Translational Research Grant.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 1, 2013; revised May 20, 2013; accepted May 26, 2013; published OnlineFirst May 31, 2013.

References

- Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. *Nat Clin Pract Oncol* 2006;3:448–57.
- Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, et al. Implementing multiplexed genotyping of non–small cell lung cancers into routine clinical practice. *Ann Oncol* 2011;22:2616–24.
- Kris M, Johnson B, Kwiatkowski D, Iafrate AJ, Wistuba II, Aronson SL, et al. Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). *J Clin Oncol* 2011;29: (suppl; abstr CRA7506).
- Li C, Fang R, Sun Y, Han X, Li F, Gao B, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. *PLoS ONE* 2011;6:e28204.
- Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non–small cell lung cancer. *Nature* 2007;448:561–6.
- Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. *Clin Cancer Res* 2008;14:6618–24.
- Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non–small cell lung cancer who harbor EML4-ALK. *J Clin Oncol* 2009;27:4247–53.
- Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Clin Cancer Res* 2008;14:4275–83.
- Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer* 2009;115:1723–33.
- Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, et al. Clinicopathologic features of non–small cell lung cancer with EML4-ALK fusion gene. *Ann Surg Oncol* 2010;17:889–97.
- Popat S, Vieira de Araújo A, Min T, Swansbury J, Dainton M, Wotherpoon A, et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. *J Thorac Oncol* 2011;6:1962–3.
- Kuo YW, Wu SG, Ho CC, Shih JY. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. *J Thorac Oncol* 2010;5:2039–40.
- Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, Bozzetti C, et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. *Lung Cancer* 2011;71:241–3.
- Martelli MP, Sozzi G, Hernandez L, Pettrossi V, Navarro A, Conte D, et al. EML4-ALK rearrangement in non–small cell lung cancer and non-tumor lung tissues. *Am J Pathol* 2009;174:661–70.
- Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. *Mol Cancer* 2010;9:188.
- Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforov S, Zheng W, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Res* 2011;71:6051–60.
- Rimkunas VM, Crosby K, Kelly M, Gu TL, Mack J, Silver M, et al. Analysis of receptor tyrosine kinase ROS1 positive tumors in non–small cell lung cancer: identification of a FIG-ROS1 fusion. *Clin Cancer Res* 2012;18:4449–57.
- Lee JK, Kim TM, Koh Y, Lee SH, Kim DW, Jeon YK, et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. *Lung Cancer* 2012;77:460–3.
- Yang J, Zhang X, Su J, Chen H, Tian H, Huang Y, et al. Concomitant EGFR mutation and EML4-ALK gene fusion in non–small cell lung cancer. *J Clin Oncol* 29: 2011 (suppl; abstr 10517).
- Rosell R, Sureda B, Costa C, Molina MA, Gimenez-Capitan A, Karachaliou N, et al. Concomitant actionable mutations and overall survival (OS) in EGFR-mutant non–small cell lung cancer (NSCLC) patients (p) included in the EURTAC trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (v3). *Ann Oncol* 23: 2012 (suppl; abstr 929).
- Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non–small cell lung cancer. *N Engl J Med* 2010;363:1693–703.
- Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non–small cell lung cancer: updated results from a phase 1 study. *Lancet Oncol* 2012;13:1011–9.
- Kim D, Ahn M, Shi Y, Martino De Pas T, Yang P, Riely GJ, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non–small cell lung cancer (NSCLC). *J Clin Oncol* 30: 2012 (suppl; abstr 7533).
- Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med* 2010;363:1734–9.
- Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, et al. Therapeutic strategies to overcome crizotinib resistance in non–small

- cell lung cancers harboring the fusion oncogene EML4-ALK. *Proc Natl Acad Sci U S A* 2011;108:7535–40.
26. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. *Sci Transl Med* 2012;4:120ra17.
 27. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. *Clin Cancer Res* 2012;18:1472–82.
 28. Kim S, Kim TM, Kim DW, Go H, Keam B, Lee SH, et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. *J Thorac Oncol* 2013;8:415–22.
 29. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. *EMBO Mol Med* 2010;2:146–58.
 30. Nishino M, Klepeis VE, Yeap BY, Bergethon K, Morales-Oyarvide V, Dias-Santagata D, et al. Histologic and cytomorphic features of ALK-rearranged lung adenocarcinomas. *Mod Pathol* 2012;25:1462–72.
 31. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science* 2001;293:876–80.
 32. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med* 2011;3:75ra26.
 33. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Med* 2005;2:e17.
 34. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst* 2005;97:339–46.
 35. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. *J Natl Compr Canc Netw* 2011;9:1335–41.
 36. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. *Clin Cancer Res* 2010;16:5581–90.
 37. Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. *Clin Cancer Res* 2011;17:1169–80.
 38. Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. *Clin Cancer Res* 2012;18:6219–26.
 39. Alsdorf WH, Clauditz TS, Hoenig T, Quaas A, Sirma H, Koenig AM, et al. Intratumoral heterogeneity of KRAS mutation is rare in non-small cell lung cancer. *Exp Mol Pathol* 2012;94:155–9.
 40. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. *J Clin Oncol* 2011;29:2972–7.
 41. Li Y, Yang T, Wei S, Wang J, Wang M, Wang Y, et al. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. *PLoS ONE* 2013;8:e52093.
 42. Martinez P, Hernández-Losa J, Montero M, Cedrés S, Castellví J, Martínez-Martí A, et al. Fluorescence *in situ* hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. *PLoS ONE* 2013;8:e52261.